hca healthcare inc. - HCA

HCA

Close Chg Chg %
335.05 -2.09 -0.62%

Closed Market

332.96

-2.09 (0.62%)

Volume: 1.51M

Last Updated:

Nov 20, 2024, 3:59 PM EDT

Company Overview: hca healthcare inc. - HCA

HCA Key Data

Open

$335.29

Day Range

327.88 - 335.35

52 Week Range

245.84 - 417.08

Market Cap

$84.88B

Shares Outstanding

253.30M

Public Float

182.35M

Beta

1.69

Rev. Per Employee

N/A

P/E Ratio

15.04

EPS

$22.61

Yield

76.99%

Dividend

$0.66

EX-DIVIDEND DATE

Dec 13, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.62M

 

HCA Performance

1 Week
 
-2.90%
 
1 Month
 
-19.86%
 
3 Months
 
-14.35%
 
1 Year
 
32.05%
 
5 Years
 
139.22%
 

HCA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 26
Full Ratings ➔

About hca healthcare inc. - HCA

HCA Healthcare, Inc. is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities. The firm operates general and acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services, and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was founded by Dr. Thomas F. Frist, Jr in 1968 and is headquartered in Nashville, TN.

HCA At a Glance

HCA Healthcare, Inc.
One Park Plaza
Nashville, Tennessee 37203-6527
Phone 1-615-344-9551 Revenue 64.97B
Industry Hospital/Nursing Management Net Income 5.24B
Sector Health Services 2023 Sales Growth 7.861%
Fiscal Year-end 12 / 2024 Employees 310,000
View SEC Filings

HCA Valuation

P/E Current 15.04
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.273
Price to Sales Ratio 1.152
Price to Book Ratio N/A
Price to Cash Flow Ratio 7.933
Enterprise Value to EBITDA 9.327
Enterprise Value to Sales 1.824
Total Debt to Enterprise Value 0.353

HCA Efficiency

Revenue/Employee 209,574.194
Income Per Employee 16,909.677
Receivables Turnover 6.519
Total Asset Turnover 1.196

HCA Liquidity

Current Ratio 1.18
Quick Ratio 1.02
Cash Ratio 0.081

HCA Profitability

Gross Margin 14.818
Operating Margin 14.818
Pretax Margin 11.861
Net Margin 8.069
Return on Assets 9.649
Return on Equity N/A
Return on Total Capital 13.077
Return on Invested Capital 14.168

HCA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 104.426
Total Debt to Total Assets 74.468
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 97.473
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Hca Healthcare Inc. - HCA

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
51.53B 58.75B 60.23B 64.97B
Sales Growth
+0.38% +14.01% +2.52% +7.86%
Cost of Goods Sold (COGS) incl D&A
44.27B 49.07B 51.18B 55.34B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.72B 2.85B 2.97B 3.08B
Depreciation
2.69B 2.83B 2.94B 3.05B
Amortization of Intangibles
28.00M 27.00M 28.00M 25.00M
COGS Growth
+1.49% +10.85% +4.29% +8.13%
Gross Income
7.26B 9.68B 9.05B 9.63B
Gross Income Growth
-5.87% +33.27% -6.46% +6.34%
Gross Profit Margin
+14.09% +16.47% +15.03% +14.82%
2020 2021 2022 2023 5-year trend
SG&A Expense
- - - -
-
Research & Development
- - - -
-
Other SG&A
- - - -
-
SGA Growth
- - - -
-
Other Operating Expense
- - - -
-
Unusual Expense
- 295.00M 12.00M 78.00M
EBIT after Unusual Expense
6.97B 9.67B 8.97B 9.63B
Non Operating Income/Expense
23.00M 1.70B 1.34B 17.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
54.00M 113.00M 45.00M 22.00M
Interest Expense
1.56B 1.53B 1.74B 1.94B
Interest Expense Growth
-15.26% -1.99% +13.73% +11.44%
Gross Interest Expense
1.56B 1.53B 1.74B 1.94B
Interest Capitalized
- - - -
-
Pretax Income
5.43B 9.83B 8.58B 7.71B
Pretax Income Growth
+3.55% +81.09% -12.74% -10.19%
Pretax Margin
+10.54% +16.74% +14.24% +11.86%
Income Tax
1.04B 2.11B 1.75B 1.61B
Income Tax - Current - Domestic
1.15B 2.08B 1.43B 1.33B
Income Tax - Current - Foreign
5.00M 15.00M 18.00M 3.00M
Income Tax - Deferred - Domestic
(112.00M) 6.00M 288.00M 262.00M
Income Tax - Deferred - Foreign
3.00M 11.00M 12.00M 19.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
54.00M 113.00M 45.00M 22.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.39B 7.72B 6.83B 6.09B
Minority Interest Expense
633.00M 765.00M 1.19B 849.00M
Net Income
3.75B 6.96B 5.64B 5.24B
Net Income Growth
+7.10% +85.30% -18.88% -7.11%
Net Margin Growth
+7.28% +11.84% +9.37% +8.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.75B 6.96B 5.64B 5.24B
Preferred Dividends
- - - -
-
Net Income Available to Common
3.75B 6.96B 5.64B 5.24B
EPS (Basic)
11.0975 21.5146 19.4353 19.2435
EPS (Basic) Growth
+8.03% +93.87% -9.66% -0.99%
Basic Shares Outstanding
338.27M 323.31M 290.35M 272.40M
EPS (Diluted)
10.9253 21.1588 19.1505 18.9644
EPS (Diluted) Growth
+8.54% +93.67% -9.49% -0.97%
Diluted Shares Outstanding
343.61M 328.75M 294.67M 276.41M
EBITDA
9.98B 12.53B 12.02B 12.70B
EBITDA Growth
+1.72% +25.52% -4.06% +5.67%
EBITDA Margin
+19.37% +21.33% +19.96% +19.55%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 409.565
Number of Ratings 26 Current Quarters Estimate 6.171
FY Report Date 12 / 2024 Current Year's Estimate 21.976
Last Quarter’s Earnings 4.90 Median PE on CY Estimate N/A
Year Ago Earnings 19.01 Next Fiscal Year Estimate 24.655
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 15 21 20
Mean Estimate 6.17 5.82 21.98 24.65
High Estimates 7.04 6.08 22.80 25.51
Low Estimate 5.84 5.60 21.60 23.73
Coefficient of Variance 4.71 2.77 1.38 1.99

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 15 15
OVERWEIGHT 4 4 5
HOLD 6 7 6
UNDERWEIGHT 1 1 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Hca Healthcare Inc. - HCA

Date Name Shares Transaction Value
Sep 13, 2024 Michael S. Cuffe EVP and Chief Clinical Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 13, 2024 Michael S. Cuffe EVP and Chief Clinical Officer 51,758 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $145.24 per share 7,517,331.92
Sep 13, 2024 Michael S. Cuffe EVP and Chief Clinical Officer 38,036 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $386.43 per share 14,698,251.48
Sep 13, 2024 Michael S. Cuffe EVP and Chief Clinical Officer 29,678 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $385.42 per share 11,438,494.76
May 29, 2024 William Robert Frist Director 11,905 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Thomas Fearn Frist Director 13,497 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Kathleen M. Whalen SVP & Chief Ethics Officer 14,179 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $133.53 per share 1,893,321.87
May 21, 2024 Kathleen M. Whalen SVP & Chief Ethics Officer 12,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $101.16 per share 1,263,893.04
May 21, 2024 Kathleen M. Whalen SVP & Chief Ethics Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2024 Kathleen M. Whalen SVP & Chief Ethics Officer 11,318 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $322.86 per share 3,654,129.48
May 21, 2024 Kathleen M. Whalen SVP & Chief Ethics Officer 9,454 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $326.3 per share 3,084,840.20
May 21, 2024 Kathleen M. Whalen SVP & Chief Ethics Officer 12,045 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 14, 2024 Erol R. Akdamar Group President 60,497 Bona fide gift 0.00
May 14, 2024 Erol R. Akdamar Group President N/A Bona fide gift 0.00
May 14, 2024 Jeff E. Cohen SVP-Government Relations 5,185 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $313 per share 1,622,905.00
May 9, 2024 Michael S. Cuffe EVP and Chief Clinical Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 7, 2024 Kathryn A Torres SVP-Payer Contracting & Align. 21,475 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $312 per share 6,700,200.00
May 7, 2024 Kathryn A Torres SVP-Payer Contracting & Align. 22,365 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $312 per share 6,977,880.00
May 2, 2024 Michael W. Michelson Director 10,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 2, 2024 Robert J. Dennis Director 25,575 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Hca Healthcare Inc. in the News